• JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
  • JoomlaWorks Simple Image Rotator
 
  Bookmark and Share
 
 
Thèse de Doctorat
DOI
10.11606/T.5.2007.tde-21062007-095821
Document
Auteur
Nom complet
Luciana Nogueira de Sousa Andrade
Adresse Mail
Unité de l'USP
Domain de Connaissance
Date de Soutenance
Editeur
São Paulo, 2007
Directeur
Jury
Chammas, Roger (Président)
Barreira, Maria Cristina Roque Antunes
Brentani, Maria Mitzi
Colquhoun, Alison
Dagli, Maria Lucia Zaidan
Titre en portugais
Evidência da dualidade funcional de galectina-3 no crescimento de melanoma murino
Mots-clés en portugais
Galectina-3
Melanoma
Neovascularização patológica
Resumé en portugais
Tumores são definidos como microambientes compostos não só pelas células malignas, mas também por células endoteliais, fibroblastos e leucócitos, que promovem o crescimento tumoral e a angiogênese. Galectina-3, uma proteína que se liga a b- galactosídeos, é abundantemente expressa por monócitos/macrófagos, dentre outros leucócitos. Inúmeras evidências sugerem que galectina-3 atua como uma molécula reguladora da resposta inflamatória. Tendo em vista que o infiltrado inflamatório pode promover a progressão de tumores, o objetivo do presente trabalho foi avaliar se galectina-3, expressa tanto pela célula tumoral como pelas células estromais, modula o crescimento de melanoma. Para tal, células de melanoma murino Tm1 foram transfectadas com o gene de galectina-3. Ambos clones celulares (galectina-3 positivos e negativos) foram injetados na intrafáscia ou no subcutâneo de camundongos (fêmeas) C57BL/6 selvagens e/ou nocautes para o gene de galectina-3 para análise da implantabilidade e crescimento tumoral. Com relação à implantabilidade, não foi observado diferenças no estabelecimento de uma massa tumoral proliferativa em animais selvagens inoculados com células Tm1 transfectadas ou não com o gene de galectina-3 em animais selvagens. Em relação a taxa de crescimento dos tumores, nenhum animal nocaute inoculado com células Tm1 galectina-3 positivas apresentou tumores de dimensões mensuráveis até o 11º dia pós-inóculo. Independente do nível de expressão de galectina- 3 pela célula tumoral, os tumores originados nos animais nocautes apresentavam menor massa em gramas comparados ao grupo selvagem, sugerindo que galectina-3 expressa pelas células estromais promove o crescimento tumoral. Ainda, os tumores originados nos animais nocautes e no grupo selvagem inoculado com células Tm1 galectina-3 positivas apresentavam menor extensão de área necrótica do que os animais selvagens inoculados com células Tm1 galectina-3 negativas. Interessantemente, os animais selvagens e nocautes inoculados com células Tm1 galectina-3 positivas apresentaram tumores com menor área vascular e menor número de estruturas vasculares funcionais quando comparados aos animais selvagens inoculados com células Tm1 galectina-3 negativas. A análise de expressão gênica nos tumores mostrou que os níveis relativos de RNAm de VEFG (fator de crescimento de endotélio vascular) foram menores nos animais inoculados com células Tm1 galectina-3 positivas em relação aos inoculados com células Tm1 galectina-3 negativas, indicando que galectina-3 expressa pelas células tumorais atua como uma molécula anti-angiogênica. Finalizando, o presente trabalho sugere que galectina-3 pode atuar como uma molécula pró- ou anti-tumoral, dependendo do tipo celular que a expressa no microambiente tumoral.
Titre en anglais
Evidence for a dual role of galectin-3 in murine melanoma growth
Mots-clés en anglais
Galectin-3
Melanoma
Neovascularization pathologic
Resumé en anglais
Tumors have been described as microenvironments composed not only by malignant cells, but also by endothelial cells, fibroblasts and leukocytes, which can promote tumor growth and angiogenesis. Galectin-3, a b-galactoside binding protein, is expressed by monocytes/macrophages and others leukocytes. In fact, several lines of evidence suggest that galectin-3 act as master regulators of the inflammatory response. Based on the fact that the inflammatory infiltrate can promote tumor progression, the proposal of this study was to evaluate if galectin-3, either from tumor or stromal cells could modulate melanoma growth. Tm1 murine melanoma cell line was transfected with the galectin-3 gene. Both clones (galectin-3 negative and positive) were injected in the foot pad or subcutaneous in female C57BL/6 wild-type (WT) and galectin-3 knock-out (KO) mice to tumor engraftment and growth analysis. There was no difference in the tumor engraftment between animas injected with Tm1 galectin-3 positive or negative cells. In addition, any knock-out mice injected with galectin-3 positive cells had measurable tumors up to day 11 post inoculation. Regardless the galectin-3 expression level in the melanoma cell, tumors from galectin-3 KO mice were smaller than those from WT animals, suggesting that galectin-3 expressed by stromal cells promotes tumor growth. Moreover, tumor necrotic area was smaller in KO mice and in wild-type animals injected with Tm1 galectin-3 positive cells compared to wild type animals injected with Tm1 galectin-3 negative cells. Interestingly, both vascular area and the number of functional vessels in animals injected with galectin-3 positive Tm1 cells were smaller in WT as well as in KO mice compared to the same animals injected with galectin-3 negative Tm1 cells. Gene expression analysis showed that VEGF (vascular endothelial growth factor) mRNA levels were smaller in wild type animals injected with Tm1 galectin-3 positive cells compared to those injected with Tm1 galectin-3 negative cells, indicating that galectin-3 expressed by tumor cells can act as an anti-angiogenic molecule. The present study suggests that galectin-3 can act either as a pro or antitumoral molecule, depending on which type of cell (tumoral or stromal) this lectin is expressed within tumor microenvironment.
 
AVERTISSEMENT - Regarde ce document est soumise à votre acceptation des conditions d'utilisation suivantes:
Ce document est uniquement à des fins privées pour la recherche et l'enseignement. Reproduction à des fins commerciales est interdite. Cette droits couvrent l'ensemble des données sur ce document ainsi que son contenu. Toute utilisation ou de copie de ce document, en totalité ou en partie, doit inclure le nom de l'auteur.
LNSA_teseDR.pdf (6.84 Mbytes)
Date de Publication
2007-07-06
 
AVERTISSEMENT: Le matériau se réfère à des documents provenant de cette thèse ou mémoire. Le contenu de ces documents est la responsabilité de l'auteur de la thèse ou mémoire.
  • CHAMMAS, R., et al. Biological applications of a novel chimeric molecule for the assessment of galectin-3 ligands [doi:10.1369/jhc.7a7174.2007]. Journal of Histochemistry and Cytochemistry [online], 2007, vol. 55, p. 1015-1026.
  • COUTINHO, E. L., et al. Anti-tumor effect of endostatin mediated by retroviral gene transfer in mice bearing renal cell carcinoma [doi:10.1096/fj.07-8412com]. The FASEB Journal [online], 2007, vol. 21, p. 3153-3161.
  • de Oliveira, Soraya I, et al. Platelet-activating factor receptor (PAF-R)-dependent pathways control tumour growth and tumour response to chemotherapy [doi:10.1186/1471-2407-10-200]. BMC Cancer [online], 2010, vol. 10, p. 200.
  • MACHADO, Camila Maria Longo, et al. Galectin-3 disruption impaired tumoral angiogenesis by reducing VEGF secretion from TGF 1-induced macrophages [doi:10.1002/cam4.173]. Cancer Medicine [online], 2014, vol. 3, p. n/a-n/a.
  • ANDRADE, L. N. S., et al. The BKB1 receptor antagonist R715 increases melanoma vascular permeability leading to improved sensitivity to the chemotherapeutic agent dacarbazine. In The 4th International Conference on Tumor Microenvironment: Progression, Therapy and Prevention, Florença, 2007. Program and Abstracts- 4th International Conference on Tumor Microenvironment., 2007. Abstract.
  • ANDRADE, L N S, et al. The double face of cell death within tumor microenvironments. In 6th International Cell Death Symposium, Angra dos Reis, 2006. The mechanisms of cell death in cancer and aging. Program and Abstract Book.., 2006. Abstract.
  • ANDRADE, L. N. S., et al. Bradykinin-dependent pathways are activated within tumor microenvironments- new targets for therapy. In 4th International conference on Tumor Microenvironment: Progression, Therapy and Prevention, Florença, 2007. Proceedings of the 4th International Conference on.Bologna : Medimond, 2007. Abstract.
  • ANDRADE, L. N. S., et al. Dual role of galectin-3 in murine melanoma growth. In VIII São Paulo Research Conference. Cancer 2007: from molecular biology to treatment, São Paulo, 2007. Applied Cancer Research ., 2007. Abstract.
  • ANDRADE, Luciana Nogueira de Sousa, et al. COMBINED EFFECTS OF DACARBAZINE AND R715, AN ANTAGONIST OF THE BRADYKININ RECEPTOR SUBTYPE I, IMPAIRED MELANOMA ASSOCIATED ANGIOGENESIS. In XXI REUNIAO ANUAL DA FESBE, Águas de Lindóia, São Paulo, 2006. CD ROOM da XXI REUNIAO ANUAL DA FESBE., 2006. Abstract.
  • ANDRADE, Luciana Nogueira de Sousa, et al. Combined effects of dacarnazine and R715, an antagonist of the bradykinin receptor subtype I, impaired mekanoma associated angiogenesis. In XIII Congresso da Sociedade Brasileira de Biologia Celular e IX Simpósio Brasileiro de Matris Extracellular, IV International Symposium on Extracellular Matrix, Búzios, Rio de Janeiro, 2006. Anais do XIII Congresso da Sociedade Brasileira de Biologia Celular e IX Simpósio Brasileiro de Matriz Extracellular, IV International Symposium on Extracellular Matrix., 2006. Abstract.
  • ANDRADE, Luciana Nogueira de Sousa, et al. Effect of WEB2170 on B16F10 melanoma growth, survival time and expression of galectin-3, CD34 and cascase-3. In XIII Congresso da Sociedade Brasileira de Biologia Celular e IX Simpósio Brasileiro de Matris Extracellular, IV International Symposium on Extracellular Matrix, Búzios, Rio de Janeiro, 2006. Anais do XIII Congresso da Sociedade Brasileira de Biologia Celular e IX Simpósio Brasileiro de Matriz Extracellular, IV International Symposium on Extracellular Matrix., 2006. Abstract.
  • ANDRADE, Luciana Nogueira de Sousa, et al. Evidence for a dual role of galectin-3 within tumor microenvironment. In XIII Congresso da Sociedade Brasileira de Biologia Celular e IX Simpósio Brasileiro de Matris Extracellular, IV International Symposium on Extracellular Matrix, Búzios, Rio de Janeiro, 2006. Anais do XIII Congresso da Sociedade Brasileira de Biologia Celular e IX Simpósio Brasileiro de Matriz Extracellular, IV International Symposium on Extracellular Matrix., 2006. Abstract.
  • ANDRADE, Luciana Nogueira de Sousa, et al. EVIDENCE FOR A DUAL ROLE OF GALECTIN-3 WITHIN TUMOR MICROENVIRONMENT. In XXI REUNIAO ANUAL DA FESBE, Águas de Lindóia, São Paulo. CD ROOM da XXI REUNIAO ANUAL DA FESBE., 2006. Abstract.
  • ANDRADE, Luciana Nogueira de Sousa, et al. Transient expression of galectin-3 interferes with the kinetics of melanoma engraftment. In IV São Paulo Research Conference Cancer Today: From Molecular Biology to Treatment, São paulo, 2005. Applied Cancer Research Supplement., 2005. Abstract.
  • COSTA, Patrícia Luisa Nunes da, et al. Combined use of the Bradykinin B1R antagonist R954 and the chemotherapeutic agent dacarbazine increased global survival of melanoma bearing mice. In XXXVI Reunião Anual da SBBq, Salvador, 2007. Anais da XXXVI Reunião Anual da SBBq., 2007. Abstract.
  • COSTA, Patrícia Luisa Nunes da, et al. Evidence for the participation of bradykinin receptor 1 positive cells in murine melanoma engraftment. In XIII Congresso da Sociedade Brasileira de Biologia Celular e IX Simpósio Brasileiro de Matris Extracellular, IV International Symposium on Extracellular Matrix, úzios, Rio de Janieo, 2006. Anais do XIII Congresso da Sociedade Brasileira de Biologia Celular e IX Simpósio Brasileiro de Matriz Extracellular, IV International Symposium on Extracellular Matrix., 2006. Abstract.
  • DUARTE, A P M, ANDRADE, L N S, and CHAMMAS, R. Ganglioside remodelling and cell survival. In SIMEC2004-Simposio Internacional sobre Matriz Extracelular, Angra dos Reis, 2004. SIMEC-2004., 2004. Abstract.
  • IKEMORI, Rafael Yamashita, et al. Analysis of galectin-3 expression in a human malignant glioma cell line: NG97. In XIII Congresso da Sociedade Brasileira de Biologia Celular e IX Simpósio Brasileiro de Matris Extracellular, IV International Symposium on Extracellular Matrix, Búzios, Rio de Janeiro, 2006. Anais do XIII Congresso da Sociedade Brasileira de Biologia Celular e IX Simpósio Brasileiro de Matriz Extracellular, IV International Symposium on Extracellular Matrix., 2006. Abstract.
  • OLIVEIRA, Soraya Imon de, et al. Impact of apoptotic cells and/or treatment with PAF-R antagonist on Ehrlich ascitic tumor and melanoma B16F10. In 8th World Congress on Inflammation, Copenhagen, 2007. Inflammation Research., 2007. Abstract.
  • OLIVEIRA, Soraya Imon de, et al. PAF receptor antagonist and dacarbazine association in B16F10 melanoma. In 13th International Congress of Immunology, Rio de Janeiro, 2007. Proceedings of the 13th International Congress of Immunology., 2007. Abstract.
  • PINHEIRO, Mônica de Campos, et al. Synergic Effects of R715, an Antagonist of the Bradykinin Receptor Subtype 1 (BKB1-R) Which Impaired angiogenesis, and Dacarbazine on Murine Melanoma. In IV São Paulo Research Conference Cancer Today: From Molecular Biology to Treatment, São Paulo, 2005. , 2005. Abstract.
  • ZIMMERMANN, Lara, et al. Galectin-3 expression, deposition in the extracellular matrix and posttranslational modifications are altered under hypoxic conditions. In Annual Meeting of the Society for Glycobiology, San Diego, 2009. Glycobiology (Oxford). : Oxford University Press, 2009. Abstract.
  • OTAKE, A H, ANDRADE, Luciana Nogueira de Sousa, and CHAMMAS, R. Ganglioside GD3 Modulates Chemotherapy Induced Cell Death In Vitro. In IV São Paulo Research Conference Cancer Today: From Molecular Biology to Treatment, São Paulo, 2005. Applied Cancer Research. Supplement., 2005. Abstract.
Tous droits de la thèse/dissertation appartiennent aux auteurs
Centro de Informática de São Carlos
Bibliothèque Numérique de Thèses et Mémoires de l'USP. Copyright © 2001-2020. Tous droits réservés.